Abstract:Abstract Deregulation of Myc and activation of hypoxia inducible factors (HIFs) frequently occur in solid tumors. In human neuroblastoma, amplification of the N-MYC gene predicts poor prognosis and resistance to therapy. Interestingly, we demonstrated here that HIF1α, but not HIF2α, is preferentially expressed in both N-MYC amplified neuroblastoma cells and primary tumors in comparison to non-amplified ones. Expression of HIF2α in N-MYC amplified cells appears to be silenced largely through DNA methylation and histone deacetylation. Interplay between N-Myc and HIF1α plays critical roles in progression of neuroblastomas. On one hand, N-Myc overrides the inhibitory function of HIF1α on cell cycle progression under hypoxia, which frequently occurs in solid tumors and is well known to inhibit cell growth. Of note, proliferation of N-MYC amplified cells is largely unaltered under hypoxia. On the other hand, HIF1α, together with N-Myc, cooperates to regulate aerobic glycolysis (the Warburg effect) of neuroblastoma. The near-universal glycolytic switch of N-MYC amplified neuroblastoma cells may be an essential tumor trait and a consequence of the cellular adaptation to intermittent hypoxia. Targeting either HIF1α or N-Myc significantly decreases expression of genes involved in glycolysis, such as lactate dehydrogenase A (LDHA), and inhibits cell proliferation in vitro under normoxia. Strikingly, N-MYC amplified cells are addicted to LDHA expression. Reduction in LDHA activity completely inhibits their proliferation under both normoxia and hypoxia. Taken together, our results demonstrate that neuroblastoma cells differentially respond to hypoxia with distinct HIFα induction patterns, and suggest the HIF1α/N-Myc axis may represent a pharmacologically tractable pathway for the potential treatment of N-MYC amplified neuroblastomas. In particular, we propose targeting LDHA may be a promising and nontoxic approach in treatment of N-MYC amplified neuroblastomas, given that depletion of LDHA expression completely inhibits growth of N-MYC amplified cells and individuals deficient in LDHA expression show no obvious symptoms under normal conditions. Citation Information: Cancer Res 2009;69(23 Suppl):C15.

Data from WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

Wdr5 Supports An N-Myc Transcriptional Complex That Drives A Protumorigenic Gene Expression Signature In Neuroblastoma

WDR5 Facilitates Recruitment of N-MYC to Conserved WDR5 Gene Targets in Neuroblastoma Cell Lines

Supplementary Dataset 4 from WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and is Activated Through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.

Data from Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α

Myc Activation Through Enhancer Hijacking Or Focal Enhancer Amplification Drives A Subset Of High-Risk Pediatric Neuroblastoma

Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis

MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription

Abstract C15: Combinatorial Regulation of Neuroblastoma Tumor Progression by HIF1α and N-myc Transcriptional Factors

MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent

The Long Noncoding RNA Lncnb1 Promotes Tumorigenesis by Interacting with Ribosomal Protein RPL35

Loss of nuclear envelope phosphatase CTDNEP1 drives aggressive medulloblastoma by triggering MYC amplification and genomic instability

Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma

N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 ( NLRR1 ) gene in neuroblastoma

JMJD6 is a Tumorigenic Factor and Therapeutic Target in Neuroblastoma

The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis

MYCN Amplification and ATRX Mutations Are Incompatible in Neuroblastoma

Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability

Abstract 2593: A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma

Conditional c-MYC activation in catecholaminergic cells drives distinct neuroendocrine tumors: neuroblastoma vs somatostatinoma